Recombinant Adenovirus-p53 Gene Therapy for Advanced Unresectable Soft-Tissue Sarcomas

• Published in: Human gene therapy Vol. 29; no. 6; p. 699
• Main Authors: Xiao, Shao Wen, Xu, Yi-Zhi, Xiao, Bu-Fan, Jiang, Jing, Liu, Chang-Qing, Fang, Zhi-Wei, Li, Dong-Ming, Li, Xiao Fan, Cai, Yong, Li, Yong Heng, Sun, Yan, Su, Xing, Zhu, Guang-Ying, Zhang, Shan Wen
• Format: Journal Article
• Language: English
• Published: United States 01.06.2018
• Subjects: Adenoviridae - genetics; Adolescent; Adult; Aged; Disease-Free Survival; Female; Genetic Therapy - adverse effects; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Recombination, Genetic; Sarcoma - genetics; Sarcoma - therapy; Treatment Outcome; Tumor Suppressor Protein p53 - genetics; Tumor Suppressor Protein p53 - metabolism; Young Adult; radiotherapy; hyperthermia; soft-tissue sarcomas; recombinant adenovirus-p53
• ISSN: 1557-7422
• DOI: 10.1089/hum.2017.103

Patients with unresectable advanced soft-tissue sarcomas (STS) receiving radiotherapy or/and chemotherapy still have a poor prognosis. This study aimed to evaluate retrospectively the efficacy and safety of recombinant adenovirus-p53 (rAd-p53) gene therapy combined with radiotherapy and hyperthermia for advanced STS. A total of 71 patients with advanced unresectable STS treated at the authors' center from April 2007 to November 2014 were included. Of these 71 patients, 36 cases received rAd-p53 therapy combined with radiotherapy and hyperthermia (p53 group), while 35 cases received radiotherapy and hyperthermia alone (control group). Short-term therapeutic efficacies, long-term survival outcomes, and adverse events were evaluated and compared between groups. Compared to the control group, the p53 group had a significantly higher disease control rate (83.33% vs. 54.29%; p = 0.008) and a lower progressive disease rate (16.67% vs. 45.71%; p = 0.018). In addition, rAd-p53 treatment significantly improved the progression-free survival and overall survival of STS patients. Cox regression indicated that rAd-p53 treatment significantly reduced the risks for disease progression or death event for STS patients. Furthermore, there was no significant difference in all adverse events, except for transient fever, which occurred in 89% of patients with rAd-p53 therapy. rAd-p53 combined with radiotherapy and hyperthermia can effectively improve the therapeutic efficacy and survival outcomes in patients with advanced unresectable STS, providing a new therapeutic strategy.